PremiumThe FlyBicycle Therapeutics price target lowered to $15 from $40 at Barclays Bicycle Therapeutics: Promising Advancements and Strong Financial Position Justify Buy Rating Promising Developments in Bicycle Therapeutics’ Pipeline Bolster Buy Rating PremiumCompany AnnouncementsBicycle Therapeutics Announces Key Leadership Changes Bicycle names Pierre Legault chairman, Eric Westin chief medical officer Promising Upside for Bicycle Therapeutics: Buy Rating Backed by Positive Clinical Data and Market Potential for ZP Treatment PremiumRatingsPromising Outlook for Bicycle Therapeutics: Strong Clinical Progress and Financial Health Justify Buy Rating Bicycle Therapeutics: Promising Clinical Advances and Strong Financial Position Support Buy Rating Bicycle Therapeutics price target lowered to $42 from $53 at Jefferies 
